September 2, 2008 - Health Discovery Corp. (HDC) said it has signed a licensing agreement with Smart Personalized Medicine LLC, founded by Richard Caruso, M.D., chairman and founder of Intergra Life Sciences) to work to develop a breast cancer prognostic test using HDC�s support vector machine (SVM) technology in collaboration with MD Anderson Cancer Center.

Under the terms of the Agreement, HDC will receive a 15 percent equity position in Smart Personalized Medicine based on up to a $5 million initial investment from Smart Personalized Medicine LLC investors. In addition, HDC will receive a per test royalty up to 7.5 percent based on net proceeds received from the sale of the new breast cancer prognostic test.

For more information; www.healthdiscoverycorp.com


Additional Content

News | FDA

April 16, 2026 — Royal Philips has received U.S. Food and Drug Administration 510(k) clearance for the Philips Spectral ...

Time April 20, 2026
arrow
News | Radiation Oncology

Jan. 8, 2026 — RefleXion Medical, an external-beam theranostic oncology company, has announced the U.S. Food and Drug ...

Time January 13, 2026
arrow
News | Prostate Cancer

Nov. 10, 2025 — Researchers at Wayne State University and the Barbara Ann Karmanos Cancer Institute have developed a ...

Time November 11, 2025
arrow
News | Imaging Software Development

June 12, 2025 — GE HealthCare has announced the combination of GE HealthCare’s proprietary features and algorithms with ...

Time June 12, 2025
arrow
News | Artificial Intelligence

September 7, 2023 — Paige, a provider of end-to-end digital pathology solutions and clinical AI, has announced a ...

Time September 07, 2023
arrow
Subscribe Now